Johann S de Bono1, Simon Chowdhury2, Susan Feyerabend3, Tony Elliott4, Enrique Grande5, Amal Melhem-Bertrandt6, Benoit Baron7, Mohammad Hirmand8, Patrick Werbrouck9, Karim Fizazi10. 1. The Institute of Cancer Research, London, UK. Electronic address: johann.de-bono@icr.ac.uk. 2. Guy's Hospital, London, UK; King's Hospital, London, UK; St Thomas' Hospital, London, UK. 3. Studienpraxis Urologie, Nürtingen, Germany. 4. The Christie Hospital, Manchester, UK. 5. Hospital Universitario Ramon y Cajal, Madrid, Spain. 6. Astellas Pharma, Inc, Northbrook, IL, USA. 7. Astellas Pharma, Inc, Leiden, the Netherlands. 8. Medivation, Inc, which was acquired by Pfizer, Inc in September 2016, San Francisco, CA, USA. 9. AZ Groeninge, Kortrijk, Belgium. 10. Institut Gustave Roussy, Paris-Sud University, Villejuif, France.
Abstract
BACKGROUND: Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective studies have not yet been reported. OBJECTIVE: To fulfil a regulatory postregistration commitment by evaluating the efficacy and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed following abiraterone acetate plus prednisone treatment. DESIGN, SETTING, AND PARTICIPANTS: Multicentre, single-arm, open-label study, enrolled patients with progressing mCRPC after ≥24 wk of abiraterone acetate plus prednisone treatment. All patients maintained castration therapy during the trial. Prior chemotherapy was allowed but not required. INTERVENTION: Patients received enzalutamide 160mg/d orally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was radiographic progression-free survival. Secondary endpoints were overall survival, prostate-specific antigen (PSA) response, and time-to-PSA progression. Safety data were also assessed. Kaplan-Meier methods were used to descriptively analyse time-to-event endpoints. RESULTS AND LIMITATIONS: Overall, 214 patients received enzalutamide treatment, 145 of whom were chemotherapy-naïve. Median radiographic progression-free survival was 8.1 mo (95% confidence interval: 6.1-8.3); median overall survival had not been reached. Unconfirmed PSA response rate was 27% (48 of 181). Median time-to-PSA progression was 5.7 mo (95% confidence interval: 5.6-5.8). The most common treatment-emergent adverse events were fatigue (32%), decreased appetite (25%), asthenia (18%), back pain (17%), and arthralgia (16%). No seizures were reported. CONCLUSIONS: Enzalutamide showed antitumour activity in some patients with mCRPC who had previously progressed following ≥24 wk of abiraterone acetate plus prednisone treatment. PATIENT SUMMARY: Patients with mCRPC who progressed on previous abiraterone acetate plus prednisone treatment, with or without prior chemotherapy, received enzalutamide. Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.
BACKGROUND:Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective studies have not yet been reported. OBJECTIVE: To fulfil a regulatory postregistration commitment by evaluating the efficacy and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed following abiraterone acetate plus prednisone treatment. DESIGN, SETTING, AND PARTICIPANTS: Multicentre, single-arm, open-label study, enrolled patients with progressing mCRPC after ≥24 wk of abiraterone acetate plus prednisone treatment. All patients maintained castration therapy during the trial. Prior chemotherapy was allowed but not required. INTERVENTION: Patients received enzalutamide 160mg/d orally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was radiographic progression-free survival. Secondary endpoints were overall survival, prostate-specific antigen (PSA) response, and time-to-PSA progression. Safety data were also assessed. Kaplan-Meier methods were used to descriptively analyse time-to-event endpoints. RESULTS AND LIMITATIONS: Overall, 214 patients received enzalutamide treatment, 145 of whom were chemotherapy-naïve. Median radiographic progression-free survival was 8.1 mo (95% confidence interval: 6.1-8.3); median overall survival had not been reached. Unconfirmed PSA response rate was 27% (48 of 181). Median time-to-PSA progression was 5.7 mo (95% confidence interval: 5.6-5.8). The most common treatment-emergent adverse events were fatigue (32%), decreased appetite (25%), asthenia (18%), back pain (17%), and arthralgia (16%). No seizures were reported. CONCLUSIONS:Enzalutamide showed antitumour activity in some patients with mCRPC who had previously progressed following ≥24 wk of abiraterone acetate plus prednisone treatment. PATIENT SUMMARY:Patients with mCRPC who progressed on previous abiraterone acetate plus prednisone treatment, with or without prior chemotherapy, received enzalutamide. Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.
Authors: Howard I Scher; Ryon P Graf; Nicole A Schreiber; Anuradha Jayaram; Eric Winquist; Brigit McLaughlin; David Lu; Martin Fleisher; Sarah Orr; Lori Lowes; Amanda Anderson; Yipeng Wang; Ryan Dittamore; Alison L Allan; Gerhardt Attard; Glenn Heller Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Ryon P Graf; Melanie Hullings; Ethan S Barnett; Emily Carbone; Ryan Dittamore; Howard I Scher Journal: Eur Urol Date: 2019-10-21 Impact factor: 20.096
Authors: Wassim Abida; Joshi J Alumkal; Rahul R Aggarwal; Michael T Schweizer; David M Nanus; Allan J Pantuck; Elisabeth I Heath; Eric Campeau; Sarah Attwell; Karen Norek; Margo Snyder; Lisa Bauman; Sanjay Lakhotia; Felix Y Feng; Eric J Small Journal: Clin Cancer Res Date: 2020-07-21 Impact factor: 12.531
Authors: Michael D Nyquist; Lisa S Ang; Alexandra Corella; Ilsa M Coleman; Michael P Meers; Anthony J Christiani; Cordell Pierce; Derek H Janssens; Hannah E Meade; Arnab Bose; Lauren Brady; Timothy Howard; Navonil De Sarkar; Sander B Frank; Ruth F Dumpit; James T Dalton; Eva Corey; Stephen R Plymate; Michael C Haffner; Elahe A Mostaghel; Peter S Nelson Journal: J Clin Invest Date: 2021-05-17 Impact factor: 14.808
Authors: Heather Payne; Angus Robinson; Bernard Rappe; Serena Hilman; Ugo De Giorgi; Steven Joniau; Roberto Bordonaro; Stéphane Mallick; Louis-Marie Dourthe; Moisés Mira Flores; Josep Gumà; Benoit Baron; Aurea Duran; Alessandra Pranzo; Alexis Serikoff; David Mott; Mike Herdman; Marco Pavesi; Maria De Santis Journal: Int J Cancer Date: 2021-11-08 Impact factor: 7.316
Authors: Samuel R Denmeade; Hao Wang; Neeraj Agarwal; David C Smith; Michael T Schweizer; Mark N Stein; Vasileios Assikis; Przemyslaw W Twardowski; Thomas W Flaig; Russell Z Szmulewitz; Jeffrey M Holzbeierlein; Ralph J Hauke; Guru Sonpavde; Jorge A Garcia; Arif Hussain; Oliver Sartor; Shifeng Mao; Harry Cao; Wei Fu; Ting Wang; Rehab Abdallah; Su Jin Lim; Vanessa Bolejack; Channing J Paller; Michael A Carducci; Mark C Markowski; Mario A Eisenberger; Emmanuel S Antonarakis Journal: J Clin Oncol Date: 2021-02-22 Impact factor: 44.544